Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration. by Ebneter, Andreas et al.
1
Vol.:(0123456789)
Scientific Reports |        (2020) 10:20256  | https://doi.org/10.1038/s41598-020-76354-1
www.nature.com/scientificreports
Two‑year outcomes of intravitreal 
aflibercept in a Swiss routine treat 
and extend regimen for patients 
with neovascular age‑related 
macular degeneration
Andreas Ebneter1,11, Stephan Michels2,3,11, Christian Pruente4,5*, Pascal Imesch6, 
Felix Eilenberger7, Susanne Oesch8, Isabelle P. Thomet‑Hunziker8 & Katja Hatz9,10
The aim of this observational study was to assess the use and outcome of intravitreal aflibercept in 
a treat and extend regimen in treatment‑naïve neovascular AMD patients in routine practice. This 
both retrospective and prospective study was conducted in four larger Swiss retina clinics (ASTERIA 
study). The primary endpoint was the mean change in best‑corrected visual acuity (BCVA) in ETDRS 
letters from baseline to 12 months. Between December 2017 and August 2018, 160 patients were 
included. For patients with available data, the mean change in BCVA was + 8.4 (± 14.4) letters at month 
12 (n = 139) and + 5.0 (± 11.4) letters at month 24 (n = 95). A mean number of 8.3 (± 2.4) injections 
were administered within the first year and 5.4 (± 2.9) injections during the second year. On average, 
the observed treatment interval at month 12 was 63.3 (± 22.0) days and increased to 69.1 (± 28.6) 
days at month 24. For 37% of the patients, a treatment interval ≥ 12 weeks was attained at month 
24. In conclusion,  intravitreal aflibercept in a Swiss real‑life treat and extend regimen resulted in 
comparable anatomic and functional outcomes as were observed in the prospective registration trials 
of aflibercept for nAMD treatment.
When VEGF inhibitors were first registered by health authorities for the treatment of neovascular age-related 
macular degeneration (nAMD), the approved dosing regimens involved fixed monthly intravitreal injections 
which proved to be ground-breaking at slowing progression of disease and improving vision in pivotal clinical 
 trials1–3. However, due to the treatment burden and economic limitations in clinical practice, anti-VEGF agents 
were subsequently more frequently used pro re nata (PRN), a reactive approach, where patients are monitored 
monthly but treated only when functional and/or anatomical parameters have worsened. Because of inherent 
systematic undertreatment and frequent reactivation, PRN treatment leads to suboptimal functional outcomes as 
reported in many real-life analyses in different  countries4. Moreover, a substantial disadvantage of PRN regimens 
is the need for frequent follow-up visits, commonly every 4 weeks. Mantel and co-workers have found that nAMD 
patients have their intrinsic individual treatment interval, ranging from 4 to 14 weeks which is relatively stable 
over time in most of  them5. Similar results were shown for intraocular VEGF level rebounds after ranibizumab 
or aflibercept treatment, however, indicating longer VEGF suppression with  aflibercept6. This goes along with 
a longer intravitreal half-life for aflibercept compared with other anti-VEGF drugs and theoretically a longer 
biologic activity in the  eye7,8.
The suboptimal functional gains seen with PRN regimens prompted the need for a new treatment regimen 
with individualised follow-up intervals and better outcomes. The proactive “treat and extend” (T&E) treatment 
approach met these requirements best. It delivered better visual results, presumably because by design this 
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regimen aims at proactively maintaining a dry or at least stable macula, which results in fewer relapses and less 
irreversible structural damage and scarring. This treatment concept was first proposed by  Spaide9 and shown 
to be effective in the LUCAS study, the first prospective clinical trial evaluating T&E for ranibizumab and 
 bevacizumab10. The advantages of T&E regimens were promptly recognised and respective treatment was adopted 
early by many clinical sites in Switzerland. This led to registration with a different treatment label for intravitreal 
aflibercept (IVT-AFL) in Switzerland compared with the US and the rest of Europe. It allowed for a T&E regimen 
of IVT-AFL already in the first year of treatment and furthermore gave the option of treating as frequently as 
every 4 weeks, if needed. This current study was initiated to gain insight into the outcome and manageability of 
T&E IVT-AFL in treatment-naïve patients with nAMD in routine clinical practice at larger Swiss retina clinics.
Materials and methods
Study design. ASTERIA was a multi-centre, observational study conducted at four ophthalmic clinics in 
Switzerland. All patients provided written informed consent and were enrolled between December 2017 and 
August 2018. Study data were documented retro- and prospectively for up to 24 months after IVT-AFL treat-
ment initiation using electronic case report forms.
Ethics approval. Ethical approval of the study was obtained via a centralized process at the Ethics Com-
mittee for north-west and central Switzerland (Project-ID: 2017-01864) which also applies to all other involved 
Ethics Committees. The study was conducted in accordance with all applicable laws and regulations, ICH-GCP 
guidelines were followed whenever applicable. The study was registered at ClinicalTrials.gov on December 11, 
2017 with the clinical trial registration number NCT03382587.
Patients. Male and female patients more than 55 years of age with treatment-naïve neovascular AMD for 
whom the decision to initiate treatment with IVT-AFL in a T&E regimen had been made according to routine 
clinical practice at the site of enrolment. Exclusion criteria were contraindications as listed in the local Summary 
of Product Characteristics (e.g. ocular or periocular infection and active or suspected intraocular inflamma-
tion). Patients with other eye diseases (e.g. advanced glaucoma or visually significant cataracts) likely to require 
surgery in the study eye, as well as patients with concomitant ocular or systemic administration of drugs within 
3 months prior to IVT-AFL initiation that could potentially interfere with or potentiate the mechanism of action 
of IVT-AFL were also excluded. Only the eye with longer IVT-AFL treatment history was considered for inclu-
sion in the study in retrospectively documented patients in whom both eyes fulfilled eligibility criteria.
Treatment. Within the scope of the study, the T&E regimen was generally defined as follows: (1) initial 
doses every 4 weeks until a dry retina or disease stability was reached; (2) afterwards, treatment intervals were 
extended if disease stability was maintained and no signs of worsening, e.g. new or recurrence of exudation (as 
measured by optical coherence tomography), haemorrhage, or visual acuity reduction were observed on the 
injection day; (3) if signs of recurrence were observed at the injection day, the subsequent treatment interval was 
shortened. The extension and shortening increments were not mandated by the protocol but were at the discre-
tion of the treating physician according to local clinical routine and varied typically between one and two weeks.
All decisions pertaining to diagnostic procedures and treatments including the decision to initiate IVT-AFL 
using T&E regimen were made by the treating physician according to routine clinical practice and independently 
of study participation. Therefore, planning and timing of visits and injections varied according to the patient’s 
need and the standards adopted by study centres.
Objectives. The primary endpoint of this study was the mean change in best-corrected visual acuity (BCVA) 
from baseline (i.e. initiation of IVT-AFL) to month 12. BCVA was assessed in accordance with each institution’s 
routine clinical practice either by using the Snellen or the Early Treatment Diabetic Retinopathy Study (ETDRS) 
charts. Further key outcomes included the mean change in BCVA from baseline to month 24, the mean change 
in central retinal thickness (CRT) as determined by spectral domain optical coherence tomography from base-
line to months 3, 12, and 24, the mean number of injections and the mean treatment intervals at months 12 
and 24, new or increasing disease activity indicated by haemorrhage, increasing pigment epithelial detachment 
(PED), intraretinal or subretinal fluid, and retinal pigment epithelial (RPE) rip within 12 and 24 months after 
IVT-AFL initiation. Additionally, safety was analysed.
Statistical analysis. All statistics were exploratory or descriptive and were performed using the SAS soft-
ware version 9.4 (SAS Institute, Cary, USA). Two analysis subsets were defined for statistical analysis: All patients 
with at least one documented IVT-AFL administration were included in the safety set (SAF set). Patients 
included in the safety set for whom BCVA assessment for the study eye was available at least for baseline and one 
further visit were included in the effectiveness set (EFF set). To account for different notations of BCVA (ETDRS 
or Snellen charts), Snellen values were converted to ETDRS letters for analysis according to Gregori et al.11. The 
analyses were performed based on the observed data at month 3 (90 ± 21 days), month 12 (360 ± 49 days), and 
month 24 (720 ± 56 days). The Spearman rank correlation was used to analyse the change in BCVA (observed 
cases) at 12 and 24 months in relation to the number of applied IVT-AFL injections. The mean change in BCVA 
and CRT between baseline and the respective timepoints for the total population were checked for significance 
using the paired t-test in a post hoc analysis. To impute missing post-baseline data, the last observation carried 
forward (LOCF) approach was used for analysis of endpoints evaluated at a specific time point (e.g. change in 
BCVA). Statistical subgroup analyses of the EFF set were additionally performed according to the type of cho-
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roidal neovascularisation (CNV) at baseline. Prism software (GraphPad Software Inc. version 7.05, San Diego, 
CA, USA) was used for data presentation.
Results
Patient disposition and baseline characteristics. Between December 2017 and August 2018, 163 
patients were enrolled. Three patients in retrospect did not fulfil eligibility criteria and were excluded from the 
analysis (Supplementary Fig. S1). In total, 160 patients were included in the SAF set. All patients were included 
retrospectively, hereof 20 patients had a partly prospective therapy documentation. For all patients, BCVA values 
were available at baseline and at one subsequent visit at least, such that all 160 patients were included in the EFF 
set which is therefore identical to the SAF set (see Supplementary Fig. S1). In total, 101 patients (63%) completed 
the study (24 months ± 8 weeks) and 59 patients (37%) discontinued study participation prematurely. Of these, 
19 patients successfully stopped therapy with IVT-AFL prior to month 24 due to the absence of disease activ-
ity, and another 12 patients stopped IVT-AFL treatment because of insufficient response. Besides, 10 patients 
changed dosing regimen (mainly to PRN), 8 patients had an interfering ophthalmic treatment (e.g. cataract 
surgery, photodynamic therapy), 4 patients were lost to follow-up, 2 patients discontinued due to adverse events, 
and 4 patients for other reasons (systemic disease or patient´s wish). Demographic data and disease characteris-
tics for the patients in the EFF set are shown in Table 1.
Change in BCVA. Baseline BCVA for patients in the EFF set with available BCVA data at month 12 (n = 139) 
was 61.5 (± 19.7) ETDRS letters (Snellen equivalent 20/125). For these patients, BCVA had significantly increased 
by 8.4 (± 14.4) letters at month 12 compared to baseline (95% CI 6.0–10.9, p < 0.01) (Fig. 1). The mean change in 
BCVA at month 12 differed nominally between the CNV type subgroups and was particularly high in patients 
with polypoidal choroidal vasculopathy (16.2 (± 22.4) letters; Fig. 1). When using the LOCF approach, the mean 
change from baseline at month 12 was 8.3 (± 14.6) letters for the total EFF set (n = 160). At 24 months after 
IVT-AFL initiation, the mean change in BCVA compared to baseline was + 5.0 (± 11.4) letters (95% CI 2.6–7.3, 
p < 0.01) for the total EFF set (n = 95 observed cases). The LOCF approach yielded a mean BCVA change of 6.6 
(± 15.4) letters at 24 months.
At months 12, 30.6% (n = 49) of the patients had gained, whereas 4.4% (n = 7) had lost 15 or more letters com-
pared to baseline. Even 24 months after IVT-AFL initiation, 25.6% of patients (n = 41) had an increase in BCVA 
of 15 or more letters, and for 6.7% (n = 11) BCVA had deteriorated by 15 or more letters compared to baseline.
Change in CRT . Starting with a mean CRT of 404.2 (± 134.5) µm, the mean change in CRT compared to 
baseline for the EFF set was − 111.6 (± 115.7) µm (95% CI − 131.3–− 91.9, p < 0.01) 3 months after IVT-AFL 
Table 1.  Patient demographics and disease characteristics at baseline (prior to initiation of IVT-AFL).
Demographic parameter/disease characteristic EFF Set (n = 160)
Age at baseline [years]
 Median (min, max) 81 (58, 97)
 Mean (SD) 80.9 (8.3)
Gender n (%)
 Female 89 (55.6)
 Male 71 (44.4)
Type of choroidal neovascularisation at baseline n (%)
 Occult 102 (63.8)
 Predominantly classic 27 (16.9)
 Polypoidal choroidal vasculopathy 13 (8.1)
 Minimally classic 9 (5.6)
 Retinal angiomatous proliferation 3 (1.9)
 Missing 6 (3.8)
Disease features at baseline n (%)
 Haemorrhage 41 (25.6)
 Pigment epithelial detachment 116 (72.5)
 Subretinal fluid 125 (78.1)
 Cystoid intraretinal fluid 92 (57.5)
 RPE rip 3 (1.9)
Baseline BCVA
 ETDRS letter score, Mean (SD)[letters] 61.5 (20.1)
 Approximate Snellen equivalent [ft] 20/125
Retinal thickness at baseline [µm]
 Mean (SD) 404.2 (134.5)
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initiation, which remained stable at 12 months (− 110.8 (± 124.9) µm; 95% CI − 131.8–− 89.8, p < 0.01) and at 
24 months (− 124.4 (± 133.3) µm; 95% CI − 148.5–− 94.3, p < 0.01). Also, for the three main CNV type subgroups, 
the CRT was nominally clearly and sustainably reduced (Fig. 2) with IVT-AFL treatment. The CRT reduction 
was particularly marked for the predominantly classic subtype.
Number of injections and treatment intervals. Patients in the EFF set received a mean of 8.3 (± 2.4) 
IVT-AFL injections in the study eye in the first year and 5.4 (± 2.9) injections in the second year (see Supple-
mentary Fig. S2 including also the number of injections of the three main CNV type subgroups). Spearman 
analysis indicated no correlation between the number of IVT-AFL injections and the mean change in BCVA 
(observed cases) at 12 months (Spearman coefficient − 0.12; p = 0.1740) or at 24 months (Spearman coefficient 
− 0.06; p = 0.5642).
Figure 1.  Mean change (± standard deviation) in best-corrected visual acuity (BCVA) at month 12 based 
on observed data for the total cohort and according to the three most common choroidal neovascularisation 
(CNV) types at baseline. PCV: polypoidal choroidal vasculopathy.
Figure 2.  Mean change in central retinal thickness (CRT) over time based on observed cases for the total 
cohort and according to the main choroidal neovascularisation (CNV) types at baseline.
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To evaluate the treatment intervals during the T&E IVT-AFL regimen, the time since the last injection at 
12 and 24 months was analysed. As shown in Fig. 3a, the mean time since last injection for the total EFF set 
increased from 63.3 (± 22.0) days at month 12 to 69.1 (± 28.1) days at month 24. For 37.0% of patients, the time 
since last injection at month 24 was 12 weeks or more. However, for some patients the time since last injection 
was still < 8 weeks at month 12 (35% of patients) and at month 24 (38% of patients) (Fig. 3b). When considering 
only treatment intervals without any new disease activity between two injections (maintained intervals), the 
last maintained intervals (SD) before 12 months (61.4 ± 22.5 days) and before 24 months (65.9 ± 28.1 days) were 
only slightly different.
Disease activity. In the 160 patients of the EFF set, new or increasing disease activity occurred in 77 patients 
(48.1%) within 12 months and in 91 patients (56.9%) within 24 months from baseline. For most of the patients 
with new or increasing disease activity during the study, the occurrences were only mild (79 patients) whereas 
the other patients (n = 12) had at least one severe occurrence as classified by the investigator.
Moreover, features associated with disease activity of specific interest were assessed in more detail. The fre-
quency of occurrence of the most important features found in eyes with new or increasing disease activity are 
shown in Fig. 4.
Safety analysis. The safety set comprised the 160 patients with at least one IVT-AFL injection. Treatment-
emergent adverse events (TEAEs) have occurred in 17 (10.6%) patients (see Supplementary Table S1). In three 
patients (1.9%) non-ocular TEAEs and in 14 patients (8.8%) ocular TEAEs were reported. Most commonly 
reported ocular TEAEs were nAMD in the fellow eye (5 patients (3.1%)), cataract operation (4 patients (2.5%)), 
Figure 3.  Mean time since last intravitreal aflibercept (IVT-AFL) injection at 12 and at 24 months after IVT-
AFL initiation analysed as continuous (a) and as categorical (b) variable based on observed cases.
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and corneal erosion (2 patients (1.3%)). No cases of endophthalmitis or intraocular inflammation were reported 
during the study.
Discussion
In recent years, T&E regimens have been increasingly used in routine clinical practice for patients with nAMD 
treated with anti-VEGF therapy. T&E approaches have been conceived to not only reduce the treatment and 
monitoring burden compared with PRN treatment, but also to gradually adapt the follow-up intervals to the 
individual needs. The proactive approach should also minimise the risk of severe recurrences of nAMD. Fur-
thermore, with T&E regimens the patient´s uncertainty about examinations and procedures during the visit is 
minimal, since an intravitreal injection is given at each scheduled encounter.
Within this observational study, the outcome of patients treated with IVT-AFL administered in a T&E regi-
men for 24 months in Swiss routine clinical practice was assessed. The patients’ mean baseline BCVA (61.5 
(± 20.1) ETDRS letters) was higher than that observed in other  interventional12 and non-interventional  studies13,14 
indicating that in Switzerland patients with nAMD are diagnosed early and rapidly treated. Despite the high 
baseline BCVA with potential ceiling effect, vision increased significantly by a mean of 8.4 (± 14.4) ETDRS let-
ters at 12 months. This is a considerably better outcome than that reported in another observational Swiss T&E 
IVT-AFL study with only a 5.7 letter  improvement15. The visual outcome in the current study is in line with the 
results of the interventional T&E IVT-AFL ATLAS  study12 and closely matches the interventional VIEW trials 
that involved fixed, bimonthly IVT-AFL  administration16 and reported vision gain of 8.4 letters in the q8 group 
after 12 months. After 24 months, a significant vision gain of 5.0 (± 11.4) ETDRS letters was observed in our 
study. The BCVA change with LOCF at 24 months was 6.6 (± 15.4) letters. The better BCVA gain in the LOCF 
analysis might have been influenced by patients who left the study early due to treatment success and potentially 
good visual outcomes. However, the further BCVA development of these patients was not recorded anymore 
in this study. Our 24 months BCVA results are in line with the 6.0 letters found by the Fight Retinal Blindness 
Study  Group17 and the 7.0 letters reported by Jaki Mekjavić et al.18, both having analysed T&E IVT-AFL under 
routine conditions.
During the first year, a mean number of 8.3 (± 2.4) injections were administered to the study eye. This roughly 
corresponds to the injection intensities seen in other routine T&E IVT-AFL studies with observation periods 
of one year, as reported by Abdin et al.19 and Yamamoto et al.20. With a mean of 5.4 (± 2.9) injections during the 
second year, the number of applied IVT-AFL injections is slightly lower than reported in some other routine 
T&E IVT-AFL  regimens17,18 but slightly higher than reported by Traine and co-workers15. However, no cor-
relation between the number of IVT-AFL injections and BCVA outcomes was found in our study. In the T&E 
regimen, patients with low disease activity require less frequent treatment while typically obtaining good BCVA 
results. This lack of correlation may therefore suggest that there was probably no systematic undertreatment in 
this study, which is discussed as one of the main reasons for a gradual decline in visual acuity over time in rou-
tine anti-VEGF  treatment21. Accordingly, there was only a slight increase in the mean time between IVT-AFL 
injections from 63.3 (± 22.0) days at months 12 to 69.1 (± 28.6) days at month 24. This may indicate that after 
one year of therapy there is only minimal change of the individual treatment interval, and relative stability can 
be reached within the first year.
At month 12, the observed treatment interval was ≥ 8 weeks for 65.2% of patients. 37.0% of patients even 
reached a treatment interval of at least 12 weeks at month 24. However, patients with premature cessation of 
IVT-AFL therapy due to the absence of disease activity were not considered in the observed cases analysis at 
24 months. Even though individual criteria may have slightly varied among the study sites, the majority of 
patients with treatment suspension due to success had consecutive injections at intervals of at least 12 weeks 
or longer without any disease recurrence before treatment was suspended. On the other hand, 38% of patients 
required treatment more frequently than every 8 weeks after 24 months of treatment. This is more intense 
Figure 4.  Features of new or increasing activity within 12 and 24 months after intravitreal aflibercept (IVT-
AFL) initiation. RPE: retinal pigment epithelium.
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treatment than the standard treatment label allowed in most countries except Switzerland. This study convinc-
ingly corroborates that one fixed treatment paradigm does not fit all, and that a considerable number of patients 
need more frequent injections than every 8 weeks. The level of intraocular VEGF suppression need varies from 
patient to patient, which confirms the content of specific individually different VEGF suppression times for 
 patients6. These findings are also important for future clinical nAMD studies, which should allow IVT-AFL 
treatment intervals of less than 8 weeks.
Besides the aforementioned aspects, it is interesting to compare our study results with those reported in the 
 ALTAIR22 and  ARIES23 studies with a focus on the baseline visual acuity and the geographic area of the study. 
In these studies, T&E regimens were used after a loading phase consisting of 3 monthly AFL injections and an 
8-weekly interval. Whereas ALTAIR was conducted in Japan and compared 2-weekly and 4-weekly extension 
intervals, the ARIES study population was predominantly Caucasian and differences between an early switch to 
T&E and a late switch were investigated. The letter gain at 12 months in the ALTAIR study was 8.4–9.0 letters, 
similar to our results, but with fewer injections (6.9–7.2). This might be explained by the lower baseline visual 
acuity (55 ETDRS letters) and a higher proportion of PCV (37% vs 8%), which in our study had the highest 
gain in BCVA. In line with this observation, during the second year only 3.6 AFL injections were necessary to 
maintain the vision gain. The mean last treatment interval was almost 2 weeks longer in ALTAIR both at 12 and 
24 months, and the proportion of patients with a last interval > 12 weeks was considerably higher (42–50% and 
57–60% at 12 months and 24 months, respectively). Overall, the results in the ARIES study are more similar 
to our findings. The letter gain from baseline was 4.3–7.9 letters at 24 months, which is comparable to the 5.0 
letters in our sample. Equally, the number of AFL injections over 104 weeks was 12–13 treatments, similar to 
the 13.7 injections reported here. The close replication of ARIES findings in our study might be due to similar 
baseline visual acuity (61 letters) and the common Caucasian background. Of note, in all these T&E studies, the 
maximal treatment interval does not change much anymore between 12 and 24 months, a finding also replicated 
in our study.
There are some limitations which are mainly due to the observational study design, prohibiting predefined 
study assessments as well as timing of visits, and the partly retrospective collection of data. On the other hand, 
these aspects prevented any type of influence on investigators´ decisions and helped to underpin the study´s 
real life setting.
In conclusion, the presented data show that a T&E regimen using AFL in Swiss routine practice resulted 
in anatomic and functional outcomes similar to those from prospective registration trials of AFL for nAMD 
treatment.
Data availability
Due to the small sample size, datasets generated during the study are not publicly available in order to ensure 
that patient privacy is safeguarded but are available from the corresponding author on reasonable request and 
with permission of the study´s funder.
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